Biomarkers Help Diagnose Mild Cognitive Impairment in Diabetics
By LabMedica International staff writers Posted on 02 Mar 2016 |
Image: Dot blots showing the expressions of total glycogen synthase kinase-3β (tGSK-3β) and p-GSK-3β (ser9) in the platelets; the differences of platelet GSK-3β activity between T2DM-nMCI group and T2DM-MCI group (Photo courtesy of Tongji Medical College).
Alzheimer's disease is the most common cause of senile dementia, and the prevalence is increasing with population aging and even when the clinical diagnosis of Alzheimer's disease is made, it is generally too late to be curable.
Type 2 diabetes mellitus (T2DM) is also an age-associated disorder, and the patients with T2DM show a significantly increased risk to suffer from Alzheimer's disease. Biomarkers that can diagnose or predict conversion of T2DM into Alzheimer's disease would make it possible to start an early intervention, and eventually reduces the incidence of Alzheimer's disease.
Scientists at the Huazhong University of Science and Technology (Wuhan, China) and their colleagues recruited 646 T2DM patients from January 2012 to May 2015 from five hospitals. Patients in each set were randomly divided into two groups: T2DM without mild cognitive impairment (MCI) (termed T2DM-nMCI) or with MCI (termed T2DM-MCI). Glycogen synthase kinase-3β (GSK-3β) activity in platelets, ApoE genotypes in leucocytes and the olfactory function were detected by Western/dot blotting.
For biochemical indicators, all participants were asked to measure fasting blood glucose, postprandial blood glucose, serum insulin, hemoglobinA1c (HbA1c) and serum magnesium, the next morning. On receipt, serum, leukocytes and platelet samples were separated from EDTA whole blood by centrifugation, which were collected and stored at -80 °C until analysis. The total GSK-3β (tGSK-3β) and serine-9 phosphorylated GSK-3β (pS9GSK-3β, the inactive form of the kinase) in serum or platelet were measured by ELISA (Cusabio Biotech Co., Ltd.; Wuhan, China), Western blotting or dot blotting. In addition, the biochemical activity of GSK-3β in platelet was measured by using enzyme activity assay kit.
The scientists found no significant differences for sex, T2DM years, hypertension, hyperlipidemia, coronary disease, complications, insulin treatment, HbA1c, ApoE ε2, ApoE ε3, tGSK3β and pS9GSK3β between the two groups. They did find that that activation of the peripheral circulating GSK-3β, expression of ApoE ε4, dysfunction of the olfactory function, and aging are diagnostic for the mild cognitive impairment in T2DM patients, and combination of these factors can significantly improve the diagnostic accuracy. They also developed a simple protocol for measuring the total and the inactivated form of GSK-3β in human platelets. As the method is simple and easy to operate with low cost and good repeatability, it is suitable for application in clinical laboratories.
Jian-Zhi Wang, PhD, a professor and senior author of the study, said, “Although we have designed training set and validation set respectively to assure the correlation of cognitive impairments with the biomarkers, further longitudinal studies are needed to confirm how informative these biomarkers in predicting the conversion of T2DM into Alzheimer's disease.” The study was published on February 13, 2016, in the journal EbioMedicine.
Related Links:
Huazhong University of Science and Technology
Cusabio Biotech
Type 2 diabetes mellitus (T2DM) is also an age-associated disorder, and the patients with T2DM show a significantly increased risk to suffer from Alzheimer's disease. Biomarkers that can diagnose or predict conversion of T2DM into Alzheimer's disease would make it possible to start an early intervention, and eventually reduces the incidence of Alzheimer's disease.
Scientists at the Huazhong University of Science and Technology (Wuhan, China) and their colleagues recruited 646 T2DM patients from January 2012 to May 2015 from five hospitals. Patients in each set were randomly divided into two groups: T2DM without mild cognitive impairment (MCI) (termed T2DM-nMCI) or with MCI (termed T2DM-MCI). Glycogen synthase kinase-3β (GSK-3β) activity in platelets, ApoE genotypes in leucocytes and the olfactory function were detected by Western/dot blotting.
For biochemical indicators, all participants were asked to measure fasting blood glucose, postprandial blood glucose, serum insulin, hemoglobinA1c (HbA1c) and serum magnesium, the next morning. On receipt, serum, leukocytes and platelet samples were separated from EDTA whole blood by centrifugation, which were collected and stored at -80 °C until analysis. The total GSK-3β (tGSK-3β) and serine-9 phosphorylated GSK-3β (pS9GSK-3β, the inactive form of the kinase) in serum or platelet were measured by ELISA (Cusabio Biotech Co., Ltd.; Wuhan, China), Western blotting or dot blotting. In addition, the biochemical activity of GSK-3β in platelet was measured by using enzyme activity assay kit.
The scientists found no significant differences for sex, T2DM years, hypertension, hyperlipidemia, coronary disease, complications, insulin treatment, HbA1c, ApoE ε2, ApoE ε3, tGSK3β and pS9GSK3β between the two groups. They did find that that activation of the peripheral circulating GSK-3β, expression of ApoE ε4, dysfunction of the olfactory function, and aging are diagnostic for the mild cognitive impairment in T2DM patients, and combination of these factors can significantly improve the diagnostic accuracy. They also developed a simple protocol for measuring the total and the inactivated form of GSK-3β in human platelets. As the method is simple and easy to operate with low cost and good repeatability, it is suitable for application in clinical laboratories.
Jian-Zhi Wang, PhD, a professor and senior author of the study, said, “Although we have designed training set and validation set respectively to assure the correlation of cognitive impairments with the biomarkers, further longitudinal studies are needed to confirm how informative these biomarkers in predicting the conversion of T2DM into Alzheimer's disease.” The study was published on February 13, 2016, in the journal EbioMedicine.
Related Links:
Huazhong University of Science and Technology
Cusabio Biotech
Latest Molecular Diagnostics News
- Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods
- Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases
- New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens
- New DNA Testing Method Offers Faster and More Accurate Pathogen Identification
- Precise Cancer Detection Method as Quick and Easy as Blood Test
- DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes